Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company Drug

3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study

Fineline Cube Dec 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...

Company Drug

Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China

Fineline Cube Dec 20, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...

Company Deals

Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions

Fineline Cube Dec 20, 2023

Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences

Fineline Cube Dec 20, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...

Company Deals

China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer

Fineline Cube Dec 19, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...

Company Deals

Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market

Fineline Cube Dec 19, 2023

Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...

Company Drug

European Commission Expands Keytruda Indications for Advanced Cancer Treatments

Fineline Cube Dec 19, 2023

The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...

Company Drug

HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD

Fineline Cube Dec 19, 2023

HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...

Company Deals

Blue Sail Medical Partners with Weifang Government on Healthcare Initiative

Fineline Cube Dec 19, 2023

China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...

Company Drug

HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors

Fineline Cube Dec 19, 2023

Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...

Company Deals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Fineline Cube Dec 19, 2023

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...

Company Drug

EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment

Fineline Cube Dec 19, 2023

Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Company Medical Device

BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit

Fineline Cube Dec 19, 2023

BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China

Fineline Cube Dec 19, 2023

According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...

Company

GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals

Fineline Cube Dec 19, 2023

In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...

Company Deals

Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement

Fineline Cube Dec 19, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...

Company Deals

WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing

Fineline Cube Dec 19, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Posts pagination

1 … 394 395 396 … 632

Recent updates

  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.